Improving biopharma BD with AI-powered due diligence
In biopharma business development, companies face increasing pressure to identify the next blockbuster drug with limited resources and time constraints.
AI
Chinese biotechs & assets, a Q&A with Kanya Rajangam, MD, PhD
Recently, I had a conversation with Dr. Kanya Rajangam, to discuss current perceptions about Chinese biotech, opportunities, language challenges, and risks.
The Great Disruption: how Chinese assets will reshape drug development
Chinese biopharma companies are at an inflection point, with rapid advances in science, know-how, and talent; these assets will reshape drug development.
AI for biopharma business development: finding the right assets faster
By combining human expertise with AI-powered analysis, we’re helping biopharma companies make faster, more informed business development decisions.
3 key ways AI-powered analysis supports drug development
Artificial intelligence-powered pipeline analysis is emerging as a tool that can help teams make better, faster drug development decisions.
5 guardrails you MUST implement when using AI in biopharma
Implementing guardrails for artificial intelligence (AI) in biopharma is crucial for ensuring effective, safe, and compliant use of this powerful technology.
4 common use cases for an AI-powered drug pipeline analysis platform
Let’s explore the four most common use cases for an AI-powered drug pipeline analysis platform and how they support strategic decision-making in biopharma.
Enabling every cure for community matters: Our AI-powered journey
Vibe Bio is doing extraordinary work to change drug development: from funding next-generation therapies to helping others identify the highest potential cures.
The Future of Aging, AI, and Robotics with CEO of Insilico Medicine
Insilico Medicine’s mission is to extend healthy, productive longevity by transforming drug discovery and development with generative artificial intelligence.
4 major disruptions to the hunt for new cures, and how AI can help
The pursuit of novel cures in the pharmaceutical industry has always been a challenging endeavor. However, within the last decade or so, the landscape has become even more complex and disruptive due to several key factors. In this blog, we explore four major disruptions impacting the hunt for new cures and how artificial intelligence (AI)…